Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -30.06% is 61% above its 5-year average of -76.50%, around the middle of its 5-year range (-193.77%–129.78%).
145.96% below its 12-month average of 65.41%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -13.39%.
RETURN ON ASSETS (ROA)
-30.06%
RETURN ON ASSETS (ROA) AVG TTM
65.41%
RETURN ON ASSETS (ROA) AVG 3Y
-56.95%
RETURN ON ASSETS (ROA) AVG 5Y
-76.50%
RETURN ON ASSETS (ROA) AVG 10Y
-206.06%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-145.96%
CURRENT VS 3Y AVG
+47.22%
CURRENT VS 5Y AVG
+60.71%
CURRENT VS 10Y AVG
+85.41%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+6.76%
vs the sector median at left
PAVmed Inc.
Market Cap
$17.04M
Return on Assets (ROA)
-30.06%
TTM Avg
65.41%
3Y Avg
-56.95%
5Y Avg
-76.50%
Market Cap
$17.11M
Return on Assets (ROA)
-49.72%
TTM Avg
-28.29%
3Y Avg
-39.08%
5Y Avg
-40.04%
Market Cap
$17.17M
Return on Assets (ROA)
-59.70%
TTM Avg
-56.25%
3Y Avg
-61.89%
5Y Avg
-61.99%
Market Cap
$16.76M
Return on Assets (ROA)
-98.29%
TTM Avg
-314.03%
3Y Avg
-259.71%
5Y Avg
-198.18%
Market Cap
$16.75M
Return on Assets (ROA)
-67.58%
TTM Avg
-90.98%
3Y Avg
-83.38%
5Y Avg
-70.12%
Market Cap
$16.53M
Return on Assets (ROA)
-68.66%
TTM Avg
-45.54%
3Y Avg
-39.28%
5Y Avg
-39.25%
Market Cap
$16.40M
Return on Assets (ROA)
-116.60%
TTM Avg
-66.28%
3Y Avg
-71.56%
5Y Avg
-63.10%
Market Cap
$17.99M
Return on Assets (ROA)
-548.74%
TTM Avg
-346.44%
3Y Avg
-242.08%
5Y Avg
-167.09%
Market Cap
$18.03M
Return on Assets (ROA)
-39.68%
TTM Avg
-29.52%
3Y Avg
-26.86%
5Y Avg
-20.28%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PAVmed Inc. (PAVM) | $17.04M | -30.06% | 65.41% | -56.95% | -76.50% |
| Lipocine Inc. (LPCN)vs › | $17.11M | -49.72% | -28.29% | -39.08% | -40.04% |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.17M | -59.70% | -56.25% | -61.89% | -61.99% |
| Palatin Technologies, Inc. (PTN)vs › | $16.76M | -98.29% | -314.03% | -259.71% | -198.18% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.75M | -67.58% | -90.98% | -83.38% | -70.12% |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.53M | -68.66% | -45.54% | -39.28% | -39.25% |
| Dyadic International, Inc. (DYAI)vs › | $16.40M | -116.60% | -66.28% | -71.56% | -63.10% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $17.99M | -548.74% | -346.44% | -242.08% | -167.09% |
| Cosmos Health Inc. (COSM)vs › | $18.03M | -39.68% | -29.52% | -26.86% | -20.28% |
| BioCardia, Inc. (BCDA)vs › | $15.93M | -154.34% | -227.23% | -240.86% | -184.63% |
ROA
-30.1%
ROE
-34.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 1.03% |
| 2024-12-31 | 129.78% |
| 2023-12-31 | -193.77% |
| 2022-12-31 | -164.84% |
| 2021-12-31 | -57.89% |
| 2020-12-31 | -173.30% |
| 2019-12-31 | -220.03% |
| 2018-12-31 | -211.49% |
| 2017-12-31 | -580.56% |
| 2016-12-31 | -649.21% |
| 2015-12-31 | -146.33% |
| 2014-12-31 | -65.17% |
